Platelet-rich plasma effective remedy for dry eye

Article

Autologous platelet-rich plasma (PRP) is a very effective treatment for severe dry eye symptoms, according to the results of a study published in the March issue of Ophthalmic Research.

Autologous platelet-rich plasma (PRP) is a very effective treatment for severe dry eye symptoms, according to the results of a study published in the March issue of Ophthalmic Research.

Jorge Alio and colleagues from the Instituto Oftalmologico de Alicante and the Universidad Migul Hernandez, Alicante, Spain, treated 18 consecutive dry eye patients with topical PRP. The researchers were looking for the disappearance of subjective symptoms, increases in best corrected visual acuity (BCVA), tear meniscus, tear break-up time and decreases in inflammation and fluorescein staining. Improvements in impression cytology were also measured.

At one-month follow-up, 89% of subjects demonstrated a significant improvement in symptoms and 28% improved by at least one line of BCVA. A significant improvement in lachrymal meniscus and conjunctival hyperaemia, and a decrease or disappearance of corneal fluorescein staining was observed. Meanwhile, impression cytology revealed a significant increase in conjunctival goblet cells.

The authors of the study conclude that autologous PRP is a very effective treatment for severe dry eye symptoms.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.